Literature DB >> 34302482

Impact of Opioid-Minimizing Pain Protocols After Burn Injury.

Deepanjli Donthula1, Christopher R Conner2, Van Thi Thanh Truong3, Charles Green3, Chuantao Jiang1,4, Michael W Wandling1,4, Spogmai Komak1,4, Todd F Huzar1,4, Sasha D Adams1,4, Daniel J Freet1,4, David J Wainwright1,4, Charles E Wade1,4, Lillian S Kao1,3,4,5, John A Harvin1,3,4,5.   

Abstract

In 2019, we implemented a pill-based, opioid-minimizing pain protocol and protocolized moderate sedation for dressing changes in order to decrease opioid exposure in burn patients. We hypothesized that these interventions would reduce inpatient opioid exposure without increasing acute pain scores. Two groups of consecutive patients admitted to the burn service were compared: Pre-group (from January 1, 2018 to July 31, 2019) and Post-group (from January 1, 2020 to June 30, 2020) from before and after the implementation of the protocols (from August 1, 2019 to December 31, 2019). We abstracted patient demographics and burn injury characteristics from the burn registry. We obtained opioid exposure and pain scale scores from the electronic medical record. The primary outcome was total morphine milligram equivalents (MMEs). Secondary outcomes included MMEs/day, pain domain-specific MMEs, and pain scores. Pain was estimated by creating a normalized pain score (range 0-1), which incorporated three different pain scales (Numeric Rating Scale, Behavioral Pain Scale, and Behavioral Pain Assessment Scale). Groups were compared using Wilcoxon rank-sum and chi-square tests. Treatment effects were estimated using Bayesian generalized linear models. There were no differences in demographics or burn characteristics between the Pre-group (n = 495) and Post-group (n = 174). The Post-group had significantly lower total MMEs (Post-group 110 MMEs [32, 325] vs Pre-group 230 [60, 840], P < .001), MMEs/day (Post-group 33 MMEs/day [15, 54] vs Pre-group 52 [27, 80], P < .001), and domain-specific total MMEs. No difference in average normalized pain scores was seen. Implementation of opioid-minimizing protocols for acute burn pain was associated with a significant reduction in inpatient opioid exposure without an increase in pain scores.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34302482      PMCID: PMC8921736          DOI: 10.1093/jbcr/irab143

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  21 in total

Review 1.  Practice guidelines for the management of pain.

Authors:  Lee Faucher; Kenneth Furukawa
Journal:  J Burn Care Res       Date:  2006 Sep-Oct       Impact factor: 1.845

2.  Multi-Modal Analgesic Strategy for Trauma: A Pragmatic Randomized Clinical Trial.

Authors:  John A Harvin; Rondel Albarado; Van Thi Thanh Truong; Charles Green; Jon E Tyson; Claudia Pedroza; Charles E Wade; Lillian S Kao
Journal:  J Am Coll Surg       Date:  2021-01-21       Impact factor: 6.113

3.  Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation.

Authors:  Peter M Grace; Keith A Strand; Erika L Galer; Daniel J Urban; Xiaohui Wang; Michael V Baratta; Timothy J Fabisiak; Nathan D Anderson; Kejun Cheng; Lisa I Greene; Debra Berkelhammer; Yingning Zhang; Amanda L Ellis; Hang Hubert Yin; Serge Campeau; Kenner C Rice; Bryan L Roth; Steven F Maier; Linda R Watkins
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

4.  Perioperative Use of Gabapentinoids for the Management of Postoperative Acute Pain: A Systematic Review and Meta-analysis.

Authors:  Michael Verret; François Lauzier; Ryan Zarychanski; Caroline Perron; Xavier Savard; Anne-Marie Pinard; Guillaume Leblanc; Marie-Joëlle Cossi; Xavier Neveu; Alexis F Turgeon
Journal:  Anesthesiology       Date:  2020-08       Impact factor: 7.892

5.  American Burn Association Guidelines on the Management of Acute Pain in the Adult Burn Patient: A Review of the Literature, a Compilation of Expert Opinion and Next Steps.

Authors:  Kathleen S Romanowski; Joshua Carson; Kate Pape; Eileen Bernal; Sam Sharar; Shelley Wiechman; Damien Carter; Yuk Ming Liu; Stephanie Nitzschke; Paul Bhalla; Jeffrey Litt; Rene Przkora; Bruce Friedman; Stephanie Popiak; James Jeng; Colleen M Ryan; Victor Joe
Journal:  J Burn Care Res       Date:  2020-11-30       Impact factor: 1.845

6.  A randomised controlled trial of paracetamol and ibuprofen with or without codeine or oxycodone as initial analgesia for adults with moderate pain from limb injury.

Authors:  Andis Graudins; Robert Meek; Jacqueline Parkinson; Diana Egerton-Warburton; Alastair Meyer
Journal:  Emerg Med Australas       Date:  2016-09-07       Impact factor: 2.151

7.  Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial.

Authors:  Andrew K Chang; Polly E Bijur; David Esses; Douglas P Barnaby; Jesse Baer
Journal:  JAMA       Date:  2017-11-07       Impact factor: 56.272

8.  A quasi-experimental, dual-center study of morphine efficacy in patients with burns.

Authors:  C E Foertsch; M W O'Hara; G P Kealey; L D Foster; E A Schumacher
Journal:  J Burn Care Rehabil       Date:  1995 Mar-Apr

9.  Implementation of a multi-modal pain regimen to decrease inpatient opioid exposure after injury.

Authors:  Shuyan Wei; Charles Green; Van Thi Thanh Truong; John Howell; Stephanie Martinez Ugarte; Rondel Albarado; Ethan A Taub; David E Meyer; Sasha D Adams; Michelle K McNutt; Laura J Moore; Bryan A Cotton; Lillian S Kao; Charles E Wade; John B Holcomb; John A Harvin
Journal:  Am J Surg       Date:  2019-10-01       Impact factor: 2.565

10.  Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis.

Authors:  Sudha Arumugam; Christine Sm Lau; Ronald S Chamberlain
Journal:  J Pain Res       Date:  2016-09-12       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.